Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ZMA001 in Healthy Subjects
NCT05967299Phase 1Active, not recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Placebo Cohort 1 with ZMA001 (2 arms). Primary endpoint: Adverse Events at day 113. Started Nov 2023; status: active, not recruiting.
02
Drugs
ZMA001
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05967299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05967299.